Niki BioSolutions, Inc. 8-K

What Happened

• Aptorum Group Ltd filed an 8-K on July 20, 2026 announcing the closing of its previously announced merger with DiamiR Biosciences Corp. The companies closed under an Agreement and Plan of Merger dated July 14, 2025 after shareholder approval and closing conditions were met.
• Immediately prior to closing, Aptorum effected a domestication (continuation) from the Cayman Islands to Delaware (DGCL §388 / Cayman Companies Act §206) and changed its name to Niki BioSolutions, Inc. The surviving public company’s common stock (par value $0.0001) now trades on Nasdaq under the symbol NIKI (CUSIP 653942102).

Key Details

• Closing date: July 20, 2026; Merger Agreement dated July 14, 2025.
• Share conversions: Aptorum shareholders received 814,375 shares of Niki common stock and 179,693 shares of Series A preferred stock. DiamiR stockholders received 1,979,216 shares of Niki common stock (no Series A preferred issued to DiamiR holders).
• Corporate actions: Niki adopted the 2026 Incentive Plan (approved per proxy), and the Management Services Agreement and the DiamiR licensing agreement terminated at closing.
• Governance: New board of directors includes Ian Huen (Chairman), Kira Sheinerman, Justin Wu (independent), Douglas Arner (independent), Laura A. Philips (independent); Alidad Mireskandari will serve as board observer. A Stockholder Agreement (filed as Exhibit 10.4) reflects a reduced ownership threshold for signatories.

Why It Matters

• The filing confirms a completed merger and a legal domicile change to Delaware, plus a Nasdaq ticker update to NIKI—important operational and governance changes for investors tracking the company.
• Shareholder capital structure was changed by the share conversions and issuance of Series A preferred stock to certain former Aptorum holders; DiamiR holders received newly issued common shares. Niki also adopted a new equity incentive plan and disclosed related transaction agreements, which affect future governance and compensation.